Research ExplorerPublicationsInfection- and malignancy-associated hemophagocytic syndrome...

Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis.

Standard

Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. / Janka, G; Imashuku, S; Janka-Schaub, Gritta; Schneider, M; Henter, J I.

In: HEMATOL ONCOL CLIN N, Vol. 12, No. 2, 2, 1998, p. 435-444.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Janka, G, Imashuku, S, Janka-Schaub, G, Schneider, M & Henter, JI 1998, 'Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis.', HEMATOL ONCOL CLIN N, vol. 12, no. 2, 2, pp. 435-444. <http://www.ncbi.nlm.nih.gov/pubmed/9561911?dopt=Citation>

APA

Janka, G., Imashuku, S., Janka-Schaub, G., Schneider, M., & Henter, J. I. (1998). Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. HEMATOL ONCOL CLIN N, 12(2), 435-444. [2]. http://www.ncbi.nlm.nih.gov/pubmed/9561911?dopt=Citation

Vancouver

Janka G, Imashuku S, Janka-Schaub G, Schneider M, Henter JI. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. HEMATOL ONCOL CLIN N. 1998;12(2):435-444. 2.

Bibtex

@article{ce519dda33a545ecb2a8dedd4092ab73,
title = "Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis.",
abstract = "Hemophagocytic lymphohistiocytosis represents a spectrum of pathogenetically different diseases in which a T-cell induced, uncontrolled activation of phagocytosing macrophages may lead to fever, organomegaly, and pancytopenia. The underlying immunologic disturbance can either be genetically transmitted, like in FHL, or acquired, as in IAHS or MAHS. Triggering infections can be found in all these diseases and do not allow a reliable differentiation. An international treatment protocol has been developed for FHL. IAHS and MAHS also have a high fatality rate, justifying immunomodulatory treatment if the disease is progressive.",
author = "G Janka and S Imashuku and Gritta Janka-Schaub and M Schneider and Henter, {J I}",
year = "1998",
language = "Deutsch",
volume = "12",
pages = "435--444",
number = "2",

}

RIS

TY - JOUR

T1 - Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis.

AU - Janka, G

AU - Imashuku, S

AU - Janka-Schaub, Gritta

AU - Schneider, M

AU - Henter, J I

PY - 1998

Y1 - 1998

N2 - Hemophagocytic lymphohistiocytosis represents a spectrum of pathogenetically different diseases in which a T-cell induced, uncontrolled activation of phagocytosing macrophages may lead to fever, organomegaly, and pancytopenia. The underlying immunologic disturbance can either be genetically transmitted, like in FHL, or acquired, as in IAHS or MAHS. Triggering infections can be found in all these diseases and do not allow a reliable differentiation. An international treatment protocol has been developed for FHL. IAHS and MAHS also have a high fatality rate, justifying immunomodulatory treatment if the disease is progressive.

AB - Hemophagocytic lymphohistiocytosis represents a spectrum of pathogenetically different diseases in which a T-cell induced, uncontrolled activation of phagocytosing macrophages may lead to fever, organomegaly, and pancytopenia. The underlying immunologic disturbance can either be genetically transmitted, like in FHL, or acquired, as in IAHS or MAHS. Triggering infections can be found in all these diseases and do not allow a reliable differentiation. An international treatment protocol has been developed for FHL. IAHS and MAHS also have a high fatality rate, justifying immunomodulatory treatment if the disease is progressive.

M3 - SCORING: Zeitschriftenaufsatz

VL - 12

SP - 435

EP - 444

IS - 2

M1 - 2

ER -